The changing landscape of diabetes treatment is witnessing a exciting shift, driven by novel incretin-based therapies. Presently, semaglutide has achieved considerable recognition, but emerging medications like tirzepatide, retatrutide, and cagrilintide are set to reshape the prospects. Tirzepati